Tezepelumab in Chinese Patients With Severe Chronic Rhinosinusitis With Nasal Polyps: A Prespecified Subgroup Analysis of the Phase 3 WAYPOINT Trial.
Li Hu, Houyong Li, Xicai Sun et al.
✦ AI-curated · Sources linked
In 30 seconds
This prespecified subgroup analysis of the phase 3, randomized WAYPOINT trial assessed tezepelumab in Chinese adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP). Participants received tezepelumab or placebo for 52 weeks. At Week 52, tezepelumab was associated with greater improvement in nasal-polyp score than placebo, with a least-squares mean difference of -2.03 (95% CI: -2.88, -1.19). Nasal congestion, loss of smell, sinonasal quality of life, imaging scores, and total symptom scores also improved. No tezepelumab-treated patients required nasal-polyp surgery or systemic glucocorticoids.
Key findings
- At Week 52, the nasal-polyp score difference versus placebo was -2.03 (95% CI: -2.88, -1.19).
- The nasal-congestion score difference versus placebo was -0.72 (95% CI: -1.23, -0.21).
- Tezepelumab improved loss-of-smell score (-0.44 [-0.82, -0.06]) and SNOT-22 total score (-16.34 [-29.80, -2.88]) versus placebo.
- No tezepelumab-treated patients required nasal-polyp surgery or systemic glucocorticoids.
Why it matters
The findings suggest that tezepelumab may improve polyp burden and multiple sinonasal outcomes in Chinese patients with severe CRSwNP, including those with relatively lower baseline eosinophil counts. This is relevant because the subgroup was described as having mixed inflammatory phenotypes, while the trial provides comparative evidence over 52 weeks in this population.
What to keep in mind
This was a prespecified subgroup analysis with 29 tezepelumab-treated and 34 placebo-treated patients; the authors state that generalizability to the broader Chinese CRSwNP population requires further investigation.